Zeina Nahleh1, Salman Otoukesh1, Alok Kumar Dwivedi2, Indika Mallawaarachchi2, Luis Sanchez1, J Salvador Saldivar3, Kayla Cataneda3, Rosalinda Heydarian1. 1. Department of Internal Medicine, Division of Hematology and Oncology, Texas Tech University Health Sciences Center El Paso, TX, USA. 2. Department of Biomedical Sciences, Division of Epidemiology and Biostatics, Texas Tech University Health Sciences Center El Paso, TX, USA. 3. Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center El Paso, TX, USA.
Abstract
UNLABELLED: Hispanics in El Paso, TX, a large American-Mexican border city constitute 85% of the population. Limited cancer research has been conducted in this population. We sought to study the prevalence of BRCA mutations among Hispanic patients of Mexican origin, identify reported Mexican founder or recurrent mutations, and study the breast cancer characteristics in mutation carriers. METHODS: Hispanic women of Mexican descent with a personal history of breast cancer, who presented consecutively for genetic cancer risk assessment, were enrolled in an Institutional Review Board-approved registry and underwent BRCA testing based on national guidelines. The characteristics of tumors and patients with positive BRCA mutation were analyzed. RESULTS: 88 patients were screened; 18 patients (20%) were BRCA carriers. Among BRCA carriers, 72% were diagnosed with breast cancer at younger than 50 years, 61% had "Triple negative disease". BRCA carriers had a significantly higher Body Mass Index (BMI) than non-carriers. Thirteen patients had BRCA1 mutations and five had BRCA2 mutations. A total of 17 deleterious BRCA Mutations were observed. Seven have been previously reported as specific genes from Mexico as country of origin. Five new mutations in BRCA carriers of Mexican descent were identified. CONCLUSION: Hispanic breast cancer patients of Mexican origin present at a younger age, and have predominantly triple negative tumors and high BMI. We identified 5 new mutations not reported previously in Hispanic BRCA carriers of Mexican descent. Interestingly, 41% of BRCA mutations identified have been reported as recurrent mutations in Hispanic individuals from Mexico as the country of origin. A more cost-effective approach to initial screening of Hispanic individuals based on country of origin is desirable and would potentially decrease the number of cases requiring complete sequencing.
UNLABELLED: Hispanics in El Paso, TX, a large American-Mexican border city constitute 85% of the population. Limited cancer research has been conducted in this population. We sought to study the prevalence of BRCA mutations among Hispanic patients of Mexican origin, identify reported Mexican founder or recurrent mutations, and study the breast cancer characteristics in mutation carriers. METHODS: Hispanic women of Mexican descent with a personal history of breast cancer, who presented consecutively for genetic cancer risk assessment, were enrolled in an Institutional Review Board-approved registry and underwent BRCA testing based on national guidelines. The characteristics of tumors and patients with positive BRCA mutation were analyzed. RESULTS: 88 patients were screened; 18 patients (20%) were BRCA carriers. Among BRCA carriers, 72% were diagnosed with breast cancer at younger than 50 years, 61% had "Triple negative disease". BRCA carriers had a significantly higher Body Mass Index (BMI) than non-carriers. Thirteen patients had BRCA1 mutations and five had BRCA2 mutations. A total of 17 deleterious BRCA Mutations were observed. Seven have been previously reported as specific genes from Mexico as country of origin. Five new mutations in BRCA carriers of Mexican descent were identified. CONCLUSION: Hispanic breast cancerpatients of Mexican origin present at a younger age, and have predominantly triple negative tumors and high BMI. We identified 5 new mutations not reported previously in Hispanic BRCA carriers of Mexican descent. Interestingly, 41% of BRCA mutations identified have been reported as recurrent mutations in Hispanic individuals from Mexico as the country of origin. A more cost-effective approach to initial screening of Hispanic individuals based on country of origin is desirable and would potentially decrease the number of cases requiring complete sequencing.
Authors: S A Vaziri; L M Krumroy; P Elson; G T Budd; G Darlington; J Myles; R R Tubbs; G Casey Journal: Clin Cancer Res Date: 2001-07 Impact factor: 12.531
Authors: José Palacios; Emiliano Honrado; Ana Osorio; Alicia Cazorla; David Sarrió; Alicia Barroso; Sandra Rodríguez; Juan C Cigudosa; Orland Diez; Carmen Alonso; Enrique Lerma; Joaquín Dopazo; Carmen Rivas; Javier Benítez Journal: Breast Cancer Res Treat Date: 2005-03 Impact factor: 4.872
Authors: Jeffrey N Weitzel; Jessica Clague; Arelis Martir-Negron; Raquel Ogaz; Josef Herzog; Charité Ricker; Chelsy Jungbluth; Cheryl Cina; Paul Duncan; Gary Unzeitig; J Salvador Saldivar; Mary Beattie; Nancy Feldman; Sharon Sand; Danielle Port; Deborah I Barragan; Esther M John; Susan L Neuhausen; Garrett P Larson Journal: J Clin Oncol Date: 2012-12-10 Impact factor: 44.544
Authors: Fernando Lara-Medina; Víctor Pérez-Sánchez; David Saavedra-Pérez; Monika Blake-Cerda; Claudia Arce; Daniel Motola-Kuba; Cynthia Villarreal-Garza; Ana Maria González-Angulo; Enrique Bargalló; Jose Luis Aguilar; Alejandro Mohar; Óscar Arrieta Journal: Cancer Date: 2011-03-08 Impact factor: 6.860
Authors: Michael J Hall; Julia E Reid; Lynn A Burbidge; Dmitry Pruss; Amie M Deffenbaugh; Cynthia Frye; Richard J Wenstrup; Brian E Ward; Thomas A Scholl; Walter W Noll Journal: Cancer Date: 2009-05-15 Impact factor: 6.860
Authors: William D Foulkes; Kelly Metcalfe; Ping Sun; Wedad M Hanna; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Olufunmilayo I Olopade; Barbara L Weber; Jane McLennan; Ivo A Olivotto; Louis R Bégin; Steven A Narod Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Sandra Filippini; Ana Blanco; Ana Fernández-Marmiesse; Vanesa Alvarez-Iglesias; Clara Ruíz-Ponte; Angel Carracedo; Ana Vega Journal: BMC Med Genet Date: 2007-06-29 Impact factor: 2.103
Authors: Filipa Lynce; Kristi D Graves; Lina Jandorf; Charite Ricker; Eida Castro; Laura Moreno; Bianca Augusto; Laura Fejerman; Susan T Vadaparampil Journal: Cancer Control Date: 2016-10 Impact factor: 3.302
Authors: Zeina Nahleh; Salman Otoukesh; Hamid Reza Mirshahidi; Anthony Loc Nguyen; Gayathri Nagaraj; Gehan Botrus; Nabeel Badri; Nabih Diab; Andres Alvarado; Luis A Sanchez; Alok K Dwivedi Journal: Cancer Med Date: 2018-05-07 Impact factor: 4.452